While at Reuters Pharma Europe in Barcelona the other week, pharmaphorum web editor Nicole Raleigh spoke with Florian Schnappauf, VP of enterprise commercial strategy at Veeva Europe, about
Australian radiopharma developer Telix Pharma and US neuroscience specialist Rapport Therapeutics have become the latest biotechs to weigh in for initial public offerings
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.